MedPath

A comparative study on the effectiveness of Risperidone versus Risperidone plus naltrexone in treatment of autistic spectrum disorder in children with 6-12 years old

Phase 3
Conditions
Autistic Disorder.
Childhood autism
Registration Number
IRCT201108155280N5
Lead Sponsor
Mashhad University of Medical Scinces
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
30
Inclusion Criteria

1- children with 4-12 years old; 2- children with at least one of the autistic spectrum disorder signs; 3- Fill out informative consent sheet in order to include the study. Exclusion criteria: 1- Children with severe medical disorders; 2- The history of severe drug sensitivity to naltrexone or risperidone.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Autism. Timepoint: weeks 0,4,8,10,14,18. Method of measurement: CARS.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath